N-Palmitoyl-D-sphingomyelin-¹³C  (Synonyms: Sphingomyelin 16:0-¹³C)

N-Palmitoyl-D-sphingomyelin-13C is a deuterated labeled N-Palmitoyl-D-sphingomyelin^[1]. N-Palmitoyl-D-sphingomyelin (Sphingomyelin 16:0) (Compound SM-03) can be used for the synthesis of lipid nanoparticles^[2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

704.02

C₃₈¹³CH₇₉N₂O₆P

144236-99-7

6254-89-3

CCCCCCCCCCCCCCC[13C](N[C@H]([C@H](O)/C=C/CCCCCCCCCCCCC)COP(OCC[N+](C)(C)C)([O-])=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Dandan LING, et al. Lipid compounds and lipid nanoparticle compositions. Patent. WO2023056914.